Methotrexate News and Research

RSS
Methotrexate is an antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.

Methotrexate is approved by the Food and Drug Administration (FDA) to be used by itself to treat the following types of gestational trophoblastic tumors, Chorioadenoma destruens, Choriocarcinoma, Hydatidiform mole. Methotrexate is also approved to be used alone or with other drugs to treat acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to keep it from spreading there, and to treat the following, breast cancer, certain types of head and neck cancer, lung cancer, advanced non-Hodgkin lymphoma (NHL), advanced mycosis fungoides (a type of cutaneous T-cell lymphoma), osteosarcoma that has not spread to other parts of the body, following surgery to remove the primary tumor. Methotrexate is also approved to treat the following non-cancer conditions, rheumatoid arthritis, severe psoriasis.
Global RA treatment market expected to increase just over $19 billion by 2020

Global RA treatment market expected to increase just over $19 billion by 2020

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Novel drug target identified for treating rheumatoid arthritis

Novel drug target identified for treating rheumatoid arthritis

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

Study: Rheumatoid arthritis nearly doubles risk of surprise heart attack

Study: Rheumatoid arthritis nearly doubles risk of surprise heart attack

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study

Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study

BMI plays role in rheumatoid arthritis patients' ability to achieve sustained remission

BMI plays role in rheumatoid arthritis patients' ability to achieve sustained remission

Crescendo Bioscience to present new data on Vectra DA at ACR Annual Meeting

Crescendo Bioscience to present new data on Vectra DA at ACR Annual Meeting

New drug combination shows promise as effective, safe treatment for rheumatoid arthritis

New drug combination shows promise as effective, safe treatment for rheumatoid arthritis

Medac Pharma launches Rasuvo (methotrexate) injection for patients with RA, pJIA and psoriasis

Medac Pharma launches Rasuvo (methotrexate) injection for patients with RA, pJIA and psoriasis

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

Timely diagnosis and treatment important to combat juvenile arthritis

Timely diagnosis and treatment important to combat juvenile arthritis

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Treating ulcerative colitis and Crohn’s disease

Treating ulcerative colitis and Crohn’s disease

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

FSC Laboratories acquires exclusive marketing rights for Aciphex Sprinkle in the U.S.

FSC Laboratories acquires exclusive marketing rights for Aciphex Sprinkle in the U.S.